- Open
- 39.60
- High
- 39.67
- Low
- 39.20
- Close
- 39.20
- Change
- -0.40 (-1.01%)
- Volume
- 11,844
| 1 Oct 2026 | 17:10:00 | Liquidity Agreement Monthly Update and TVR |
| 30 Sept 2026 | 07:00:06 | 2026 Interim Results |
| 23 Sept 2026 | 07:00:04 | Notice of Results |
| 8 Sept 2026 | 07:00:05 | Launch of IVDR-Certified Yourgene® DPYD Assay |
Novacyt S.A. is an international molecular diagnostics company that develops, manufactures, and commercializes a range of molecular assays and instrumentation. Its operations are divided into three segments: Clinical, which offers in vitro diagnostic products in reproductive health, precision medicine, and infectious diseases; Instrumentation, which includes DNA sample preparation platforms and PCR machines; and Research Use Only services for the life sciences sector. Novacyt serves customers in human health, animal health, and environmental markets, with a commercial presence in over 65 countries, including significant operations in Europe, North America, and Asia-Pacific.
| 1 Oct 2026 | 17:10:00 | Liquidity Agreement Monthly Update and TVR |
| 30 Sept 2026 | 07:00:06 | 2026 Interim Results |
| 23 Sept 2026 | 07:00:04 | Notice of Results |
| 8 Sept 2026 | 07:00:05 | Launch of IVDR-Certified Yourgene® DPYD Assay |
Novacyt S.A. is an international molecular diagnostics company that develops, manufactures, and commercializes a range of molecular assays and instrumentation. Its operations are divided into three segments: Clinical, which offers in vitro diagnostic products in reproductive health, precision medicine, and infectious diseases; Instrumentation, which includes DNA sample preparation platforms and PCR machines; and Research Use Only services for the life sciences sector. Novacyt serves customers in human health, animal health, and environmental markets, with a commercial presence in over 65 countries, including significant operations in Europe, North America, and Asia-Pacific.
| 1 Sept 2026 |
| 12:30:00 |
| Total Voting Rights |
| 1 Sept 2026 |
| AIM movers: Finseta hit by Middle east conflict and Likewise rises on Headlam administration |
| 1 Sept 2026 |
| 12:30:00 |
| Total Voting Rights |
| 1 Sept 2026 |
| AIM movers: Finseta hit by Middle east conflict and Likewise rises on Headlam administration |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £290m | -0.1% | |
| £105m | -0.1% | |
| £55m | -0.3% | |
| £36m | -0.4% | |
NCYTNovacyt S.A. | £28m | -0.0% |
| £21m | +0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £290m | -0.1% | |
| £105m | -0.1% | |
| £55m | -0.3% | |
| £36m | -0.4% | |
NCYTNovacyt S.A. | £28m | -0.0% |
| £21m | +0.4% |
